CDTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cidara Therapeutics's Accounts Payable for the quarter that ended in Sep. 2024 was $2.97 Mil.
Cidara Therapeutics's quarterly Accounts Payable declined from Mar. 2024 ($5.06 Mil) to Jun. 2024 ($2.29 Mil) but then increased from Jun. 2024 ($2.29 Mil) to Sep. 2024 ($2.97 Mil).
Cidara Therapeutics's annual Accounts Payable increased from Dec. 2021 ($1.30 Mil) to Dec. 2022 ($1.45 Mil) and increased from Dec. 2022 ($1.45 Mil) to Dec. 2023 ($3.77 Mil).
The historical data trend for Cidara Therapeutics's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cidara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Payable | Get a 7-Day Free Trial | 1.89 | 4.57 | 1.30 | 1.45 | 3.77 |
Cidara Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accounts Payable | Get a 7-Day Free Trial | 3.66 | 3.77 | 5.06 | 2.29 | 2.97 |
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Thank you for viewing the detailed overview of Cidara Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Leslie Tari | officer: Chief Scientific Officer | C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121 |
Taylor Sandison | officer: Chief Medical Officer | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Jeffrey Stein | director, officer: President & CEO | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Shane Ward | officer: CHIEF LEGAL OFFICER | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Preetam Shah | officer: CFO & CBO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Paul Daruwala | officer: Chief Medical Officer | 6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
Brady Johnson | officer: Dir. of Finance & Controller | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Timothy R Franson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Carin Canale-theakston | director | C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121 |
Bonnie L Bassler | director | REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591 |
James E. Levine | officer: Chief Financial Officer | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Theodore R Schroeder | director | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Chrysa Mineo | director | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
David L Gollaher | director | 6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
Daniel D Burgess | director | C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired • 08-13-2024
By Marketwired • 09-19-2024
By Marketwired • 05-15-2024
By Marketwired • 05-15-2024
By Marketwired • 10-31-2024
By GuruFocus News • 11-27-2024
By Marketwired • 11-19-2024
By Marketwired • 04-26-2024
By Marketwired • 07-03-2024
By GlobeNewswire • 10-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.